Treatment of essential thrombocythemia with anagrelide

Murali M. Chintagumpala, Laura L. Kennedy, C. Philip Steuber

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET. (J PEDIATR 1995; 127:495-8).

Original languageEnglish (US)
Pages (from-to)495-498
Number of pages4
JournalThe Journal of Pediatrics
Issue number3
StatePublished - Sep 1995

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Treatment of essential thrombocythemia with anagrelide'. Together they form a unique fingerprint.

Cite this